US 12,077,571 B2
Polyomavirus neutralizing antibodies
Johanna Abend, Emeryville, CA (US); Zorica Dragic, Basel (CH); Adam Lloyd Feire, Hull, MA (US); Mark Knapp, Oakland, CA (US); Steven Kovacs, Randolph, NJ (US); Elisabetta Traggiai, Basel (CH); Lichun Wang, Shanghai (CN); Yongqiang Wang, Shanghai (CN); Danqing Wu, Shanghai (CN); Qilong Wu, Shanghai (CN); and Fangmin Xu, Belmont, MA (US)
Assigned to NOVARTIS AG, Basel (CH)
Filed by Novartis AG, Basel (CH)
Filed on Mar. 17, 2023, as Appl. No. 18/186,064.
Application 18/186,064 is a continuation of application No. 17/502,910, filed on Oct. 15, 2021, granted, now 11,639,378.
Application 17/502,910 is a continuation of application No. 16/657,855, filed on Oct. 18, 2019, granted, now 11,161,894, issued on Nov. 2, 2021.
Application 16/657,855 is a continuation of application No. 15/758,491, granted, now 10,450,366, issued on Oct. 22, 2019, previously published as PCT/IB2016/055339, filed on Sep. 8, 2016.
Prior Publication US 2023/0399382 A1, Dec. 14, 2023
Int. Cl. A61K 45/06 (2006.01); A61K 9/19 (2006.01); A61K 39/42 (2006.01); C07K 16/08 (2006.01)
CPC C07K 16/084 (2013.01) [A61K 9/19 (2013.01); A61K 39/42 (2013.01); A61K 45/06 (2013.01); C07K 2317/20 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/41 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 20 Claims
 
1. An isolated antibody or antigen binding fragment thereof comprising:
a heavy chain variable region (vH) that comprises (a) a HCDR1 (CDR-Complementarity Determining Region) of SEQ ID NO: 226, (b) a HCDR2 of SEQ ID NO: 227, and (c) a HCDR3 of SEQ ID NO: 228; and
a light chain variable region (vL) that comprises: (d) a LCDRI of SEQ ID NO: 236, (e) a LCDR2 of SEQ ID NO: 237, and (f) a LCDR3 of SEQ ID NO: 238.